Author Identifier

John Olynyk

ORCID : 0000-0003-0417-3411

Document Type

Journal Article

Publication Title

World Journal of Gastroenterology

Volume

27

Issue

29

First Page

4831

Last Page

4845

Publisher

Baishideng Publishing Group Inc.

School

School of Medical and Health Sciences

RAS ID

36592

Comments

Khoo, T., Lam, D., & Olynyk, J. K. (2021). Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World Journal of Gastroenterology, 27(29), 4831-4845. https://doi.org/10.3748/wjg.v27.i29.4831

Abstract

Chronic infections with the hepatitis B and C viruses have significant worldwide health and economic impacts. Previous treatments for hepatitis C such as interferon and ribavirin therapy were ineffective and poorly tolerated by patients. The introduction of directly acting curative antiviral therapy for hepatitis C and the wider use of nucleos(t)ide analogues for suppression of chronic Hepatitis B infection have resulted in many positive developments. Decreasing the prevalence of hepatitis B and C have concurrently reduced transmission rates and hence, the number of new infections. Antiviral treatments have decreased the rates of liver decompensation and as a result, lowered hospitalisation and mortality rates for both chronic hepatitis B and C infection. The quality of life of chronically infected patients has also been improved significantly by modern treatment. Antiviral therapy has stopped the progression of liver disease to cirrhosis in certain patient cohorts and prevented ongoing hepatocellular damage in patients with existing cirrhosis. Longer term benefits of antiviral therapy include a reduced risk of developing hepatocellular carcinoma and decreased number of patients requiring liver transplantation. This review article assesses the literature and summarises the impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes from liver disease.

DOI

10.3748/wjg.v27.i29.4831

Creative Commons License

Creative Commons Attribution-Noncommercial 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Included in

Diseases Commons

Share

 
COinS